Last updated 3 months ago

Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

80 patients around the world
Available in Spain, Argentina, United States
Neurocrine Biosciences
1Research sites
80Patients around the world
This study is for people with
Dyskinesia
Cerebral Palsy
Requirements for the patient
To 70 Years
All Gender
Medical requirements
Sites
Instituto de Neurología Cognitiva (INECO)
Recruiting
Marcelo Torcuato de Alvear 1632, C1021 Cdad. Autónoma de Buenos Aires, Argentina
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy